Still a loss, but 85% smaller the the last quarter despite a 100% increase in both research and developement and selling and administrative costs. At least we're heading in the right direction, and the increased costs will bear fruit. A nice FY profit is still being projected by several analyst. Meda has invested heavily in promoting Onsolis but it won't be until the 4th quarter numbers are in that we'll know how well their efforts are producing and they'll boost the sp. Prior to that product or partnering news will give us an upside jolt. Patience will be nicely rewarded.